GLOW
GHK‑Cu + BPC‑157 + TB‑500: Triple Peptide Blend
Also referenced as: GHK-Cu / BPC-157 / TB-500 Blend · Triple Peptide Research Blend · GHK + BPC + TB Stack
≥99% Purity
Full Panel COA
UPS 2-Day Air
Shipment Insurance Included
Certificate Of Analysis
| Test | Result | Status |
|---|---|---|
| Identity & Purity (Avg, HPLC + MS) | 99.39% | PASS |
| Net Peptide Weight (Avg) | 73.8 mg | PASS |
| Heavy Metals (ICP-MS) | <0.010 ppb/vial | PASS |
| Endotoxins (LAL Assay) | <0.05 EU/mL | PASS |
| Sterility (DNA Microarray) | Not Included In This COA | N/A |
Made in cGMP- and ISO-certified facilities our supply chain has vetted in person, then independently multi-lab tested by Virtus with a final Certificate of Analysis from ILS Laboratories. We pay more to source this way because we hold the highest standard for the product and for you.
Batch 961234 · Tested May 12, 2026 · Motzz Laboratory, Inc.
View the full Certificate of Analysis →Curated research on GLOW
Pickart L (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data Int J Mol Sci.
PMID: 29986520 →Seiwerth S (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing Front Pharmacol.
PMID: 34267654 →Goldstein AL (2005). Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues Trends Mol Med.
PMID: 16099219 →Bock-Marquette I (2004). Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair Nature.
PMID: 15580368 →
About GLOW
A precision triple-peptide research blend combining GHK-Cu (50mg), BPC-157 (10mg), and TB-500 (10mg) in a single 70mg lyophilized vial. Formulated for researchers studying the synergistic interactions of copper-binding tripeptides and synthetic peptide analogues across cellular signaling, extracellular matrix modeling, and actin-binding pathway research.
GHK-Cu modulates extracellular matrix composition and metal-ion interaction pathways. BPC-157 is investigated for its role in angiogenesis pathway research and cytokine modulation in cellular models. TB-500 contributes to actin-binding protein upregulation and cell migration studies. Each component has been independently investigated in peer-reviewed preclinical literature.
Also Referenced As
GHK-Cu / BPC-157 / TB-500 Blend · Triple Peptide Research Blend · GHK + BPC + TB Stack
Specifications
- Scientific Name
- GHK-Cu + BPC-157 + TB-500: Triple Peptide Research Blend
- CAS Number
- 49557-75-7 / 137525-51-0 / 77591-33-4
- Molecular Formula
- GHK-Cu C₁₄H₂₄CuN₆O₄ · BPC-157 C₆₂H₉₈N₁₆O₂₂ · TB-500 C₂₁₂H₃₅₀N₅₆O₇₈S
- Molecular Weight
- Blend: GHK-Cu 403.9 g/mol · BPC-157 1419.54 g/mol · TB-500 4963.49 g/mol
- Physical Form
- Lyophilized powder
- Purity
- 99%+
- Batch Number
- 08648
- Storage
- −20°C, protected from light
Storage & Handling
Lyophilized peptides remain stable for 12–24 months when stored properly. Follow standard laboratory protocols for handling.
Storage
Store lyophilized peptide at −20°C in a standard laboratory freezer, protected from light, moisture, and heat. Avoid repeated freeze-thaw cycles.
Shelf Life
Lyophilized form remains stable for 12–24 months at −20°C in the original sealed vial. Always reference the batch-specific COA for verified shelf-life data.
Mechanism & Research Background
GLOW combines three of the most extensively studied research peptides into a single 70mg lyophilized vial: GHK-Cu (50mg), BPC-157 (10mg), and TB-500 (10mg). The component selection reflects a research design rationale grounded in the distinct, complementary cellular pathways each peptide engages: copper-binding tripeptide chemistry (GHK-Cu), gastric pentadecapeptide signaling (BPC-157), and actin-sequestering protein activity (TB-500 / thymosin β4 fragment). Each component has been independently characterized in peer-reviewed preclinical literature, allowing researchers to investigate potential synergistic interactions across multiple cellular signaling axes in controlled in-vitro environments.
In receptor and pathway research, the three components engage non-overlapping mechanisms. GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper) acts as a copper-ion shuttle and transcriptional modulator, with characterized effects on extracellular matrix turnover, redox balance, and gene-expression networks examined extensively by Pickart and colleagues (Int J Mol Sci, 2018; Biomed Res Int, 2015). BPC-157 (Body Protection Compound 157) is a synthetic 15-amino acid pentadecapeptide derived from a sequence in human gastric juice; its research literature spans angiogenesis pathway modulation, nitric oxide signaling, and cytokine regulation (Seiwerth et al., Front Pharmacol, 2021). TB-500 is a synthetic fragment of thymosin β4 with characterized actin-sequestering and cell-migration activity (Goldstein et al., Trends Mol Med, 2005).
The blend formulation is intended for research applications where investigators want to study combined or sequential exposure to all three peptides without the variability introduced by three separately reconstituted preparations. Each batch is independently tested at ILS Laboratories for purity, identity, net peptide weight, heavy metals, endotoxin, and sterility; the Certificate of Analysis reflects the combined-peptide composition. Products supplied by Virtus Peptides are intended exclusively for in-vitro laboratory research and are not for human or animal use.
Frequently Researched Questions
What is GLOW?
GLOW is a precision research blend combining three peptides in a single 70mg lyophilized vial: GHK-Cu (50mg), BPC-157 (10mg), and TB-500 (10mg). The blend is formulated for researchers studying potential synergistic interactions across copper-binding tripeptide chemistry, gastric pentadecapeptide signaling, and actin-sequestering protein activity in controlled in-vitro environments.
What are the three peptides in GLOW and how much of each?
GLOW contains 50mg GHK-Cu, 10mg BPC-157, and 10mg TB-500, a total of 70mg lyophilized peptide per vial. Each component has been independently characterized in peer-reviewed preclinical research literature on PubMed.
Why combine these three peptides specifically?
The component selection reflects three complementary, non-overlapping cellular pathways: GHK-Cu modulates extracellular matrix turnover and redox balance; BPC-157 has been studied in angiogenesis pathway and cytokine signaling research; TB-500 contributes characterized actin-sequestering and cell-migration activity. The blend allows researchers to examine combined exposure without the experimental variability of three separately reconstituted preparations.
Is GLOW tested differently than single-compound products?
Every batch of GLOW is independently tested by ILS Laboratories (ISO/IEC 17025 accredited) across the full QC panel: identity and purity by HPLC and LC-MS, net peptide weight, heavy metals by ICP-MS, bacterial endotoxin, and a rapid sterility screen. Purity and net peptide weight are averaged across three vials per batch to confirm conformity. The Certificate of Analysis reflects the combined-peptide composition.
What is the storage recommendation for GLOW?
Lyophilized GLOW should be stored at −20°C, protected from light, in the original sealed vial. Repeated freeze-thaw cycles should be avoided. When stored correctly, lyophilized peptides typically maintain stability for 12–24 months.
Where can I find published research on the components of GLOW?
PubMed indexes peer-reviewed research on each component independently: search "GHK-Cu" or "Pickart" for the copper-binding tripeptide literature, "BPC-157" or "Seiwerth Sikiric" for the gastric pentadecapeptide research, and "TB-500" or "Thymosin beta-4" for the thymosin β4 fragment literature.
